Thomas Reiss – författare

Astonishing. Searingly honest with plenty of drama it is the true story of a young life led that promised much, delivered more than could ever have been envisaged until the bottom fell out of the author's world.Quintessentially, this is a beautiful memoir by a truly remarkable man. Read it. You'll be surprised by what you may learn.

The internationalization of research and technology is one key component of the globalization of trade and business, with potentially major impacts on patterns of economic development and public policies worldwide. Although certain aspects of this internationalization trend are well documented, and some effects can be quantified, the overall processes are extremely complex and the outcomes are highly uncertain. The existence of the phenomenon is generally accepted, but its importance and the trends are currently the topic of a lively debate. This study on "New Ways in Drug Development in Pharmaceuticals" is part of a three year project which aims at investigating how new concepts of industrial knowledge creation are implemented in the different environ­ ments of the innovation systems of the United States and Germany. The main focus of the overall project is a series of case studies of innovation practice in different national and sectoral contexts. The following sectors and technological fields are investigated: pharmaceuticals and new ways in drug development by the Fraunhofer Institute for Systems and Innovation Research (ISI), advanced materials by the University Hohenheim, Insti­ tute of International Management and Innovation (Alexander Gerybadze), financial services and home banking by the Massachusetts Institute of Tech­ nology (MIT), Center for Industrial Performance (Richard Lester) and the Sloan School of Management (Edward Roberts). Financially the project was supported by the German-American Academic Council, the German Federal Minstry of Education, Science Research and Technology and the Fraunhofer Society.

The internationalization of research and technology is one key component of the globalization of trade and business, with potentially major impacts on patterns of economic development and public policies worldwide. Although certain aspects of this internationalization trend are well documented, and some effects can be quantified, the overall processes are extremely complex and the outcomes are highly uncertain. The existence of the phenomenon is generally accepted, but its importance and the trends are currently the topic of a lively debate. This study on "New Ways in Drug Development in Pharmaceuticals" is part of a three year project which aims at investigating how new concepts of industrial knowledge creation are implemented in the different environ­ ments of the innovation systems of the United States and Germany. The main focus of the overall project is a series of case studies of innovation practice in different national and sectoral contexts. The following sectors and technological fields are investigated: pharmaceuticals and new ways in drug development by the Fraunhofer Institute for Systems and Innovation Research (ISI), advanced materials by the University Hohenheim, Insti­ tute of International Management and Innovation (Alexander Gerybadze), financial services and home banking by the Massachusetts Institute of Tech­ nology (MIT), Center for Industrial Performance (Richard Lester) and the Sloan School of Management (Edward Roberts). Financially the project was supported by the German-American Academic Council, the German Federal Minstry of Education, Science Research and Technology and the Fraunhofer Society.

The internationalization of research and technology is one key component of the globalization of trade and business, with potentially major impacts on patterns of economic development and public policies worldwide. Although certain aspects of this internationalization trend are well documented, and some effects can be quantified, the overall processes are extremely complex and the outcomes are highly uncertain. The existence of the phenomenon is generally accepted, but its importance and the trends are currently the topic of a lively debate. This study on "New Ways in Drug Development in Pharmaceuticals" is part of a three year project which aims at investigating how new concepts of industrial knowledge creation are implemented in the different environ­ ments of the innovation systems of the United States and Germany. The main focus of the overall project is a series of case studies of innovation practice in different national and sectoral contexts. The following sectors and technological fields are investigated: pharmaceuticals and new ways in drug development by the Fraunhofer Institute for Systems and Innovation Research (ISI), advanced materials by the University Hohenheim, Insti­ tute of International Management and Innovation (Alexander Gerybadze), financial services and home banking by the Massachusetts Institute of Tech­ nology (MIT), Center for Industrial Performance (Richard Lester) and the Sloan School of Management (Edward Roberts). Financially the project was supported by the German-American Academic Council, the German Federal Minstry of Education, Science Research and Technology and the Fraunhofer Society.

Die Regulierungstechnik der Gentechnik in der Bundesrepublik Deutschland wird von interessierter Seite als entscheidender Grund für die Abwanderung von Wissenschaftlern und Industrie angeführt. Hierbei werden die Zustände in den wichtigsten Konkurrenzländern als sehr viel günstiger dargestellt. Auf der Basis einer internationalen Bestandsaufnahme der Regulierung der Gentechnik in den USA, Japan, Frankreich, Großbritannien und der Niederlande kommt das vorliegende Buch zu dem Schluß, daß die deutsche Regulierungspraxis zwar durchaus verbesserungswürdig ist, aber kein ausschlaggebender Grund für die Abwanderung der Industrie sein kann. Zur Verbesserung der deutschen Regulierungssituation werden eine Reihe von praktischen Empfehlungen abgeleitet.

Das Buch zeigt, wie sich die Biotechnologie auf regionaler Ebene entwickelt, mit welchen Problemfeldern Unternehmen und Forschungseinrichtungen konfrontiert sind, wie die Akteure aus Forschung, Wirtschaft und Politik sowie dem Umfeld der Biotechnologie zusammenwirken und welche Perspektiven sich für die Biotechnologie auch auf regionaler Ebene eröffnen. Von einer empirischen Analyse für das Land Baden-Württemberg ausgehend, werden technologiepolitische Optionen abgeleitet und förderpolitische Instrumente und Maßnahmen diskutiert.